Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dendritic cell vaccine added to standard radiochemotherapy for newly diagnosed glioblastoma
2017-000304-14Phase 2Active
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Feb 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in glioblastoma (GBM) (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Overall survival. Started Feb 2017; status: active.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2017-000304-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000304-14.